BiotechTube

Durvalumab

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adenocarcinoma of the Pancreas

Conditions

Adenocarcinoma of the Pancreas

Trial Timeline

Nov 9, 2018 → Jul 9, 2020

NCT ID
NCT03490760

About Durvalumab

Durvalumab is a phase 2 stage product being developed by AstraZeneca for Adenocarcinoma of the Pancreas. The current trial status is terminated. This product is registered under clinical trial identifier NCT03490760. Target conditions include Adenocarcinoma of the Pancreas.

What happened to similar drugs?

1 of 20 similar drugs in Adenocarcinoma of the Pancreas were approved

Approved (1) Terminated (0) Active (19)
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
🔄Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
🔄CT-P16 + AvastinCelltrionPhase 3
🔄Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3
🔄Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT06992609Phase 3Recruiting
NCT06826677Pre-clinicalCompleted
NCT05925530Phase 2Active
NCT04944173Phase 2Withdrawn
NCT05924880Phase 3Completed
NCT05617963Phase 2Recruiting
NCT05683977Pre-clinicalActive
NCT05303532Phase 3Recruiting
NCT05215106Phase 2Recruiting
NCT04416633ApprovedCompleted
NCT05933044Pre-clinicalCompleted
NCT04765709Phase 2Terminated
NCT04667312Pre-clinicalCompleted
NCT04062708Phase 2Active
NCT04230408Phase 2Completed
NCT04441138Phase 2Terminated
NCT05267392Phase 1/2UNKNOWN
NCT04543110Phase 2UNKNOWN
NCT04716946Phase 2Active
NCT04642469Phase 3Completed

Competing Products

20 competing products in Adenocarcinoma of the Pancreas

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
ACR-368 + GemcitabineAcrivon TherapeuticsPhase 2
32
RamucirumabEli LillyPhase 1/2
32
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
40
BA3182BioAtlaPhase 1
26
Ramucirumab (IMC-1121B ) + PaclitaxelEli LillyPhase 1
29
CT-P16 + AvastinCelltrionPhase 3
40
Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3
40
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
44
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
42
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
DS-8201aDaiichi SankyoPhase 1
29
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
39
EnzalutamideAstellas PharmaPhase 2
35
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44